Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$3.33 -5.1%	$3.71	$2.76 ▼ $13.50	$181.17M	N/A	445,130 shs	571,316 shs
CTMX CytomX Therapeutics	$2.38	$2.38	$0.40 ▼ $3.10	$192.28M	2.05	2.22 million shs	673,020 shs
RNXT RenovoRx	$1.30	$1.30	$0.75 ▼ $1.69	$47.54M	1.27	103,775 shs	128,984 shs
SXTC China SXT Pharmaceuticals	$1.65 -2.7%	$1.71	$0.95 ▼ $10.24	$191.04M	1.18	1.19 million shs	35,664 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	0.00%	-5.40%	+10.63%	-33.40%	-73.53%
CTMX CytomX Therapeutics	0.00%	-1.65%	+12.80%	+262.80%	+65.28%
RNXT RenovoRx	0.00%	+1.17%	-5.80%	+27.45%	+2.36%
SXTC China SXT Pharmaceuticals	0.00%	-6.00%	-12.96%	-23.84%	-81.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	Company Ownership	Earnings & Valuation
ALMS Alumis	2.6911 of 5 stars	3.6	0.0	0.0	3.3	1.3
CTMX CytomX Therapeutics	3.7689 of 5 stars	3.5	1.0	4.7	1.7	1.3
RNXT RenovoRx	1.6608 of 5 stars	3.5	3.0	0.0	1.7	0.0
SXTC China SXT Pharmaceuticals	0.4802 of 5 stars	0.0	5.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	3.22	Buy	$22.86	586.40% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	124.09% Upside
RNXT RenovoRx	3.00	Buy	$7.25	457.69% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RNXT, ALMS, SXTC, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$18.00
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50
5/19/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/15/2025	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $25.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/30/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/28/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
4/22/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	N/A	N/A	N/A	N/A	$5.51 per share	N/A
CTMX CytomX Therapeutics	$138.10M	1.39	$0.36 per share	6.59	($0.01) per share	-238.00
RNXT RenovoRx	$40K	1,188.53	N/A	N/A	$0.19 per share	6.84
SXTC China SXT Pharmaceuticals	$1.93M	98.90	N/A	N/A	$243.66 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$294.23M	N/A	0.00	N/A	N/A	N/A	-406.27%	-107.29%	8/12/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.48	4.96	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
RNXT RenovoRx	-$8.81M	-$0.40	N/A	N/A	N/A	N/A	-119.58%	-88.01%	8/14/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest RNXT, ALMS, SXTC, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CTMX CytomX Therapeutics	-$0.05	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	RNXT RenovoRx	-$0.08	N/A	N/A	N/A	$0.25 million	N/A
8/12/2025	Q2 2025	ALMS Alumis	-$1.11	N/A	N/A	N/A	$1.80 million	N/A
5/15/2025	Q1 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.23 million	$0.20 million
5/14/2025	Q1 2025	ALMS Alumis	-$1.47	-$1.82	-$0.35	-$1.82	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	3.73	3.73
CTMX CytomX Therapeutics	N/A	1.73	1.73
RNXT RenovoRx	N/A	9.07	9.07
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
CTMX CytomX Therapeutics	67.77%
RNXT RenovoRx	3.10%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	40.70%
CTMX CytomX Therapeutics	6.60%
RNXT RenovoRx	9.13%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	54.41 million	32.26 million	N/A
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
RNXT RenovoRx	6	36.57 million	33.23 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable

RNXT, ALMS, SXTC, and CTMX Headlines

Recent News About These Companies

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Price Down 10.1% - Here's Why

July 8, 2025 | marketbeat.com

China SXT Pharmaceuticals, Inc. (SXTC) - Yahoo Finance

July 4, 2025 | sg.finance.yahoo.com

China SXT Pharmaceuticals Inc News (SXTC) - Investing.com

June 25, 2025 | investing.com

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.comM

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.comB

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

china sxt pharmaceuticals - SXTC

October 3, 2024 | foxbusiness.com

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Short Interest Report

October 1, 2024 | benzinga.com

Can China SXT Pharmaceuticals Inc (SXTC) Stock rise from its doldrums?

July 24, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT, ALMS, SXTC, and CTMX Company Descriptions

Alumis NASDAQ:ALMS

$3.33 -0.18 (-5.13%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.34 +0.02 (+0.45%)

As of 07/18/2025 07:58 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

CytomX Therapeutics NASDAQ:CTMX

$2.38 0.00 (0.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.40 +0.02 (+0.84%)

As of 07/18/2025 07:50 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

RenovoRx NASDAQ:RNXT

$1.30 0.00 (0.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.32 +0.02 (+1.54%)

As of 07/18/2025 07:12 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.64 -0.05 (-2.66%)

Closing price 07/18/2025 03:57 PM Eastern

Extended Trading

$1.62 -0.02 (-1.52%)

As of 07/18/2025 07:49 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time